Liquid absorbing core for heat evapotranspiration, method for heat evapotranspiration, and product for heat evapotranspiration

Abstract

To provide a liquid absorbing core for a heat evapotranspiration for efficiently evapotranspirating an aqueous component for heat evapotranspiration regardless of continuous or intermittent conduction heating conditions, and a method for heat evapotranspiration and a product for heat evapotranspiration using the same.SOLUTION: A liquid absorbing core for heat evapotranspiration for evapotranspirating a chemical liquid containing a heat-evapotranspirative active component, solvent, and water, the liquid absorbing core being formed by adhesively heating the composite fiber using a thermosetting resin, in which a liquid absorption rate of the liquid absorbing core for heat evapotranspiration is 40-70%. Also provided are a method for heat evapotranspiration and a product for heat evapotranspiration using the same.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a liquid-absorbent wick for thermal evaporation, a thermal evaporation method using the same, and a thermal evaporation product. [Background technology]

[0002] Conventionally, a liquid thermal evaporation agent is absorbed into a thermal evaporation liquid absorbent wick, which is then heated to evaporate the active ingredient contained in the thermal evaporation agent, thereby obtaining the medicinal effect of the active ingredient. Thermal evaporation compositions containing pyrethroid compounds or the like as active ingredients are widely used as thermal evaporation agents, and various studies have been conducted. Since active ingredients such as pyrethroid compounds are oily, most of them are formulated by dissolving them in an oily solvent such as kerosene.

[0003] On the other hand, in order to achieve greater safety, aqueous compositions for thermal evaporation containing water or aqueous solvents such as glycol ether have been studied. For example, Patent Document 1 discloses an aqueous composition for thermal evaporation for controlling mosquitoes with reduced susceptibility to pyrethroid insecticidal components, which contains 0.1 to 3.0 mass% of a pyrethroid insecticidal component, 10 to 70 mass% of at least one glycol ether compound with a boiling point of 150 to 300°C as an aid for dealing with reduced susceptibility to the insecticidal component, and water. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2016 / 140172 Summary of the Invention [Problem to be solved by the invention]

[0005] However, because the aqueous composition for thermal evaporation contains an aqueous solvent, clogging of the liquid-absorbent wick for thermal evaporation occurs, or the supply of liquid to the aqueous composition cannot keep up with the evaporation caused by heating, causing the tip of the liquid-absorbent wick for thermal evaporation to dry out (hereinafter also referred to as "dried tip of the wick"), which is likely to result in a decrease in the amount of evaporation. Therefore, when heating is intermittent, the tip of the wick will dry out and recover intermittently, resulting in a problem of unstable evaporation amount.

[0006] Therefore, an object of the present invention is to provide a liquid-absorbent wick for thermal evaporation that can efficiently evaporate an aqueous composition for thermal evaporation regardless of whether the heating conditions are continuous or intermittent, as well as a thermal evaporation method and a thermal evaporation product using the same. [Means for solving the problem]

[0007] The present inventors have discovered that the above-mentioned problems can be solved by a liquid-absorbent wick for thermal evaporation, which is made of synthetic fibers that have been bonded and heat-molded with a thermosetting resin and has a liquid absorption rate within a specific range, and have completed the present invention.

[0008] That is, the present invention is as follows. 1. A liquid-absorbent wick for thermal evaporation, for evaporating a medicinal solution containing a thermally evaporable active ingredient, a solvent, and water, The liquid-absorbent wick for thermal evaporation is a liquid-absorbent wick in which synthetic fibers are bonded and heated with a thermosetting resin, The liquid-absorbent wick for thermal evaporation has a liquid absorption rate of 40 to 70%. 2. A method for thermal evaporation using the liquid-absorbent wick for thermal evaporation described in 1 above. 3. A product for thermal evaporation comprising the liquid-absorbent wick for thermal evaporation described in 1 above and a medicinal solution containing a thermally evaporable active ingredient, a solvent, and water. [Effects of the Invention]

[0009] The liquid-absorbent wick for thermal evaporation of the present invention has a liquid absorption rate within a specific range and is made of synthetic fibers that have been bonded and heated with a thermosetting resin, and therefore can efficiently evaporate an aqueous composition for thermal evaporation regardless of whether the heating conditions are continuous or intermittent electrical current. [Brief explanation of the drawings]

[0010] [Figure 1] FIG. 1 is a schematic diagram showing an example of a thermal evaporation method using a liquid-absorbent wick for thermal evaporation according to this embodiment. DETAILED DESCRIPTION OF THE INVENTION

[0011] The liquid-absorbent wick for thermal evaporation, the thermal evaporation method, and the product for thermal evaporation according to the present invention will be described below based on embodiments, but the present invention is not limited to these embodiments.

[0012] (Liquid absorption core) The liquid-absorbent wick for thermal evaporation of this embodiment is a liquid-absorbent wick for thermal evaporation in which synthetic fibers are bonded and heat-molded with a thermosetting resin, and achieves the desired effects by satisfying the physical property values for liquid absorption rate.

[0013] In this specification, the term "liquid absorption rate" refers to the rate at which an absorbent wick is immersed in a chemical solution and the weight of the liquid absorbed is measured relative to the weight of the absorbent wick. For example, if the weight of the absorbent wick is 1000 mg and 100 mg of liquid is absorbed, the liquid absorption rate is expressed as 10%.

[0014] Specifically, the liquid absorption rate can be measured by a method including the following steps 1) to 4). 1) Measure the weight of one absorbent wick when dry. 2) Immerse the absorbent wick in the chemical solution. 3) After the absorbent wick has been thoroughly soaked in the chemical solution, the weight of the absorbent wick (weight of the absorbent wick after absorbing the liquid) is measured. 4) Calculate the liquid absorption rate (%) using the following formula. Absorption rate (%) = [weight of absorbent wick after absorption (g) - weight of absorbent wick when dry (g)] / weight of absorbent wick when dry (g) × 100

[0015] The liquid-absorbent wick for thermal evaporation of this embodiment has a liquid absorption rate of 40 to 70%. The liquid absorption rate is more preferably 45% or higher, and even more preferably 50% or higher. The liquid absorption rate is more preferably 69% or lower, and even more preferably 68% or lower. An absorption rate of 40% or higher can increase the liquid absorption rate and stabilize the amount of evaporation of the liquid medicine regardless of whether the heating is performed under continuous or intermittent electrical current. An absorption rate of 70% or lower can ensure the strength of the wick itself. Furthermore, since the liquid medicine is absorbed into the liquid-absorbent wick by capillary action, if the liquid absorption rate exceeds 70%, the liquid absorption rate decreases, which may result in an unstable amount of evaporation of the liquid medicine.

[0016] The liquid absorption rate can be adjusted by adjusting the porosity and dry density of the liquid absorbent wick, and the water content and viscosity of the chemical solution. Specific examples of the means for adjusting the liquid absorption rate within the above range include the following. 1a) The porosity of the liquid-absorbent wick for thermal evaporation is preferably 40 to 60%, more preferably 42 to 55%. 1b) The dry density of the liquid-absorbent wick for thermal evaporation is preferably 0.40 to 0.85 g / cm 3 , more preferably 0.50 to 0.80 g / cm 3 Let's say. 1c) The water content in the chemical solution is preferably 0.5 to 27.9 mass %, more preferably 4.7 to 22.9 mass %. 1d) The viscosity of the liquid medicine is preferably 0.8 to 500 mPa·s, and more preferably 0.9 to 100 mPa·s.

[0017] In one embodiment of the liquid-absorbent wick for thermal evaporation of this embodiment, the liquid absorption rate evaluated using a chemical solution A of the following composition is preferably 40 to 70%, more preferably 45 to 69%, and even more preferably 50 to 68%. When the liquid absorption rate evaluated using the chemical solution A is 40% or more, the liquid absorption rate can be increased, and the amount of evaporation of the chemical solution can be stabilized regardless of whether the heating condition is continuous or intermittent electrical current. When the liquid absorption rate evaluated using the chemical solution A is 70% or less, the strength of the wick itself can be ensured. Furthermore, since the chemical solution is absorbed into the liquid-absorbent wick by capillary action, if the liquid absorption rate exceeds 70%, the liquid absorption rate decreases, which may result in an unstable amount of evaporation of the chemical solution. Chemical solution A: Metofluthrin 0.4% by mass, hexylene glycol 90% by mass, balance water

[0018] The liquid-absorbent wick for thermal evaporation of this embodiment has a dry density of 0.40 to 0.85 g / cm 3 The dry density is preferably 0.50 g / cm 3 More preferably, 0.60 g / cm or more is more preferable, and even more preferably 0.60 g / cm 3 That's all. The dry density is 0.80 g / cm 3 Less than 0.75 g / cm is more preferable, and even more preferable is 0.75 g / cm 3 Dry density is 0.40 g / cm or less. 3 This ensures the strength of the core itself. Dry density is 0.85g / cm 3 By satisfying this condition, the liquid absorption rate can be improved and the amount of evaporation can be further stabilized.

[0019] The liquid-absorbent wick for thermal evaporation of this embodiment has a saturated liquid absorption capacity per volume of 0.30 to 0.60 g / cm 3 The saturated liquid absorption per volume is preferably 0.35 g / cm 3 More preferably, 0.38 g / cm or more is more preferable, and even more preferably 0.38 g / cm 3 The saturated liquid absorption per volume is 0.50 g / cm 3 Less than 0.45 g / cm is more preferable, and even more preferable is 0.45 g / cm 3 When the saturated liquid absorption amount per volume is within the above range, the liquid absorption rate can be improved and the amount of evaporation can be further stabilized.

[0020] The liquid-absorbent wick for thermal evaporation of this embodiment preferably has a liquid-absorption rate of 100 to 500 mm / hour. Having a liquid-absorption rate within this range makes it easier to ensure a sufficient amount of evaporation. The liquid-absorption rate is preferably 100 mm / hour or higher, more preferably 150 mm / hour or higher, and even more preferably 200 mm / hour or higher. The liquid-absorption rate is preferably 500 mm / hour or lower, more preferably 400 mm / hour or lower, and even more preferably 300 mm / hour or lower. In this specification, the term "liquid-absorption rate (mm / hour)" refers to the rate per hour (60 minutes) measured when the liquid-absorbent wick is placed vertically on the bottom of a container filled with a liquid medicine to a height of 10 mm, and the height of the liquid medicine absorbed by the liquid-absorbent wick (height from the liquid medicine surface) after 10 minutes in this state is measured and multiplied by six.

[0021] In the liquid-absorbent wick for thermal evaporation of this embodiment, the ratio (%) of the "amount of evaporation (g) under continuous current-flow conditions" to the "amount of evaporation (g) under intermittent current-flow conditions," as calculated by the following formula, is preferably 60% or more, more preferably 80% or more, and even more preferably 90% or more. A ratio of 60% or more can make the amount of evaporation more stable regardless of whether the heating conditions are continuous or intermittent current-flow. The upper limit of this ratio is not particularly limited, but is, for example, 120% or less. Note that intermittent current-flow refers to repeatedly turning on and off the power to the thermal evaporation device (for example, repeatedly turning on the power for 12 hours and then stopping the power for 12 hours), and continuous current-flow refers to continuously turning on the thermal evaporation device. The ratio of transpiration (g) under continuous current conditions to that under intermittent current conditions (current condition ratio (continuous / intermittent) (%)) = [transpiration (g) under continuous current conditions / transpiration (g) under intermittent current conditions] × 100

[0022] Transpiration rate under intermittent power conditions The "amount of evaporation (g) under intermittent current application conditions" is determined by the following steps a1) to a5). a1) Fill 45 mL of the drug solution into a bottle for thermal evaporation, and then insert an inner stopper equipped with an absorbent wick for thermal evaporation to prepare a test sample. a2) The weight of the test sample is measured using an electronic balance, and this weight is taken as the initial sample weight. a3) The test specimen is attached to a thermal evaporation device [Earth No-Mat (registered trademark), manufactured by Earth Chemical Co., Ltd.], and electricity is turned on to the thermal evaporation device in a room adjusted to 27±2°C. The thermal evaporation device is turned on for 12 hours and off for 12 hours, repeatedly per day. a4) After 14 days (a total of 7 days) from the start of the current application, the power to the heating vaporization device is stopped and the test specimen is collected. The weight of the test specimen is measured using an electronic balance, and this weight is the weight of the specimen after 7 days of current application. a5) Calculate the amount of transpiration per day using the formula below and use this as the "amount of transpiration (g) under intermittent power supply conditions." Formula: Daily transpiration rate (g / day) = [(initial specimen weight (g)) - (total specimen weight after 7 days of application (g))] / 7 (days)

[0023] Transpiration rate under continuous power supply conditions The "amount of evaporation (g) under continuous current-carrying conditions" is determined by the following steps b1) to b5). b1) Fill 45 mL of the drug solution into a heating evaporation bottle, and then insert an inner stopper equipped with a heating evaporation absorbent wick to prepare a test sample. b2) Measure the weight of the test specimen using an electronic balance and use this as the initial specimen weight. b3) The test specimen is attached to a heating evaporation device [Earth No-Mat (registered trademark), manufactured by Earth Chemical Co., Ltd.], and electricity is turned on to the heating evaporation device in a room adjusted to 27±2°C. b4) Seven days after the start of the electrical current application, the electrical current application to the heating vaporization device is stopped and the test specimen is collected. The weight of the test specimen is measured using an electronic balance, and this is the weight of the specimen after seven days of electrical current application. b5) Calculate the amount of transpiration per day using the formula below and use this as the "amount of transpiration under continuous power supply conditions (g)." Formula: Daily transpiration rate (g / day) = [(initial specimen weight (g)) - (specimen weight after 7 days of application (g))] / 7 (days)

[0024] The liquid-absorbent wick for thermal evaporation of this embodiment is formed by bonding and heat-molding synthetic fibers with a thermosetting resin. Examples of synthetic fibers include polyester fibers, acrylic fibers, polyamide fibers, and rayon fibers. The synthetic fibers preferably have a single-filament thickness of 0.2 to 15 denier (0.222 to 16.7 dtex), more preferably 0.5 to 10 denier (0.556 to 11.1 dtex), and even more preferably 1 to 5 denier (1.11 to 5.56 dtex). By having the single-filament thickness within the above range, the liquid-absorbent wick does not become clogged, and the evaporation rate can be more stabilized.

[0025] Examples of thermosetting resins include triazine-based resins, epoxy-based resins, polyurethane-based resins, phenol-based resins, and urea-based resins. Among these, triazine-based resins, epoxy-based resins, and polyurethane-based resins are particularly preferred. These may be used alone or in combination of two or more in any ratio.

[0026] The liquid-absorbent wick for thermal evaporation of this embodiment may contain, as needed, dyes such as malachite green or other pigments, antifungal agents such as sorbic acid or salts thereof and dehydroacetic acid or other preservatives, antioxidants, agents for improving water resistance or oil resistance, sulfur, strength improvers such as zinc chloride, and the like, within limits that do not impair the properties of the wick.

[0027] The liquid-absorbent wick for thermal evaporation of this embodiment can be produced by converging synthetic fibers in the longitudinal direction, passing them through a molding die for thermal processing, impregnating them with a thermosetting resin liquid, drying, bonding, and then grinding them to the desired outer diameter and overall length. Alternatively, the liquid-absorbent wick can be produced by needle-punching synthetic fibers to form felt and then processing the needle-punched felt with a resin. The shape of the liquid-absorbent wick is not particularly limited, and examples include strips, cylinders, and rods.

[0028] When the liquid-absorbent wick for thermal evaporation of this embodiment is shaped like a rod, the outer diameter is preferably 2 to 10 mm, more preferably 3 to 9 mm, and even more preferably 4 to 8 mm, and the total length is preferably 50 to 90 mm, more preferably 55 to 85 mm, and even more preferably 60 to 80 mm, although this depends on the shape and dimensions of the container for storing the drug solution, the required liquid absorption rate, and the like.

[0029] The liquid-absorbent wick for thermal evaporation of this embodiment is suitable as a liquid-absorbent wick used in a liquid-type thermal evaporation method in which various medicinal ingredients are evaporated by heating for purposes such as insecticidal, sterilizing, mildew-proofing, fragrance, and deodorizing.

[0030] (medicinal solution) The chemical solution in this embodiment is a chemical solution containing a thermally volatile active ingredient, a solvent, and water. The active ingredient evaporates when heated and can be appropriately selected depending on the application of the aqueous chemical for thermal evaporation. Examples of the active ingredient include insecticides, repellents, bactericides / fungicides, deodorizers / deodorizers, and fragrances.

[0031] Examples of insecticides include pyrethroid compounds such as metofluthrin, allethrin, phthalthrin, resmethrin, furamethrin, fenothrin, permethrin, empenthrin, 1-ethynyl-2-ethyl-2-pentenyl-2,2,3,3-tetramethyl-cyclopropanecarboxylate, 1-ethynyl-2-methyl-2-pentenyl-2,2-dimethyl-3-(2',2'-dichlorovinyl)-cyclopropanecarboxylate, prallethrin, tefluthrin, transfluthrin, and profluthrin; carbamethrin compounds such as propoxur and carbaryl; oxadiazole compounds such as metoxadiazone; phenylpyrazole compounds such as fipronil; sulfonamide compounds such as amidoflumet; hormone agents such as neonicotinoid compounds such as dinotefuran and imidacloprid, insect juvenile hormone agents such as methoprene and hydroprene, anti-juvenile hormone agents such as precocene, and molting hormone agents such as ecdysone; and essential oils such as phytoncides, peppermint oil, orange oil, cinnamon oil, benzyl alcohol, and clove oil.

[0032] Examples of repellents include DEET, paramenthan-3,8-diol, rotenone, di-n-butyl succinate, hydroxyanisole, ethyl 3-(Nn-butyl-N-acetylamino)propionate, and 1-piperidinecarboxylic acid 2-(2-hydroxyethyl)-1-methylpropyl ester.

[0033] Examples of bactericidal and antifungal agents include isopropylmethylphenol, parachlorometaxylenol, triclosan, 3-iodomethyl-2-propenyl butylcarbamate, 2-(4-thiazolyl)benzimidazole, cetylpyridium chloride, 4-4-dimethyl-1,3-oxazolidine, poly(hexamethyl)biguanide hydrochloride, hinokitiol, and essential oils such as origanum oil, cinnamon oil, lemongrass oil, peppermint oil, and eucalyptus oil.

[0034] Examples of deodorants and deodorizing agents include lauryl methacrylate, geranyl crotonate, catechin, polyphenols, and the like.

[0035] The fragrance may be either a natural fragrance or a synthetic fragrance, or may be a compound fragrance. The type of fragrance may be either an animal-derived fragrance or a plant-derived fragrance.

[0036] Examples of natural fragrances include animal fragrances such as musk, spirit cat fragrance, and dragon jasmine fragrance; rose oil, lavender oil, peppermint oil, lemon oil, abies oil, ajokun oil, almond oil, angelica root oil, peper oil, bergamot oil, perch oil, boa burdock oil, kayabuchi oil, gananga oil, capsicum oil, caraway oil, cardamom oil, cassia oil, celery oil, cinnamon oil, citronella oil, cognac oil, and coriander oil. Examples of plant-based flavorings include bay leaf oil, cupebu oil, garlic oil, ginger oil, grapefruit oil, hop oil, juniper berry oil, laurel leaf oil, lemon oil, lemongrass oil, rosehip oil, mace oil, nutmeg oil, mandarin oil, tangerine oil, mustard oil, lampflower oil, onion oil, pepper oil, orange oil, sage oil, star anise oil, turpentine oil, wormwood oil, and vanilla bean extract.

[0037] Examples of synthetic fragrances or blended fragrances include hydrocarbons such as pinene and limonene; alcohols such as linalool, geraniol, citronellol, menthol, borneol, benzyl alcohol, and anise alcohol; phenols such as anethole and eugenol; aldehydes such as n-butyraldehyde, isobutyraldehyde, citral, citronellal, benzaldehyde, cinnamic aldehyde, and vanillin; ketones such as carvone, menthone, and camphor; lactones or oxides such as amylbutyrolactone, ethyl methylphenylglycidate, γ-nonyl lactone, coumarin, and cineole; and esters such as isopropyl isobutyrate, guanyl isovalerate, ethyl myristate, ethyl benzoate, benzyl benzoate, cinnamyl cinnamate, and methyl salicylate.

[0038] The active ingredient may be used alone or in combination of two or more. The content of the active ingredient in the drug solution may be adjusted appropriately to achieve the desired effect, taking into consideration the type of drug, the type of solvent, and the combination thereof.

[0039] The content of the active ingredient in the drug solution is preferably 0.004 to 3.5% by mass, more preferably 0.01 to 2.3% by mass, and even more preferably 0.04 to 1.2% by mass.

[0040] Examples of the solvent include organic solvents. Examples of the organic solvent include hydrocarbon solvents such as paraffinic hydrocarbons and unsaturated aliphatic hydrocarbons, glycols such as glycerin, propylene glycol, and hexylene glycol, alcohols such as methanol, isopropanol, 1-octanol, and 1-dodecanol, ketones such as acetone and acetophenone, ethers such as dihexyl ether and diethylene glycol diethyl ether, esters such as dioctyl adipate, diethyl malonate, and diethyl phthalate, xylene, chlorthene, chloroform, and silicone oil. Among these, glycols and ethers are particularly preferred, and glycols having 4 to 6 carbon atoms and a 1,3-butylene glycol skeleton are more preferred. Furthermore, it is preferable to use at least one selected from the group consisting of 1,3-butylene glycol, isoprene glycol, and hexylene glycol.

[0041] The solvent may be used alone or in combination of two or more. The type and content of the solvent in the chemical solution may be appropriately determined so as to achieve the desired effect, taking into consideration the composition of the chemical solution, etc.

[0042] The content of the organic solvent in the chemical solution is preferably 72 to 96 mass %, more preferably 77 to 93 mass %, and even more preferably 82 to 91 mass %.

[0043] The water used can be that used in chemicals for thermal evaporation, such as distilled water, RO water, ion-exchanged water, tap water, etc. The water content in the chemical solution is preferably 0.5 to 27.9 mass%, more preferably 4.7 to 22.9 mass%, and even more preferably 7.8 to 17.9 mass%.

[0044] The chemical solution of this embodiment may contain other components, such as organic solvents, surfactants, stabilizers, and dyes, as long as the effects of the present invention are not impaired.

[0045] In this embodiment, the viscosity of the chemical solution at a liquid temperature of 20°C is preferably 0.8 to 500 mPa·s, more preferably 0.9 to 100 mPa·s, and even more preferably 1 to 50 mPa·s. By setting the viscosity of the chemical solution within this range, the liquid absorption rate can be increased and the amount of evaporation of the chemical solution can be stabilized regardless of whether the electrical heating is continuous or intermittent. One way to set the viscosity within this range is to adjust the amount of thickener added to the chemical solution. The viscosity can be measured using a Brookfield viscometer (H2 rotor).

[0046] (Thermal evaporation method) An example of a thermal evaporation method using the liquid-absorbent wick for thermal evaporation of this embodiment will be described with reference to the drawings, but the liquid-absorbent wick for thermal evaporation and the product for thermal evaporation of this embodiment are not limited to the forms shown in the drawings.

[0047] In Fig. 1, reference numeral 3 denotes a liquid medicine container containing a liquid medicine, and the container 3 is detachably housed and held within a storage container 6. The top of the storage container 6 is open, and a ring-shaped or semi-ring-shaped (e.g., horseshoe-shaped) heating element 4 is fixed to this open portion. A liquid-absorbent wick 1 is held at the top of the container 3 by a wick support 2, and the top of the liquid-absorbent wick 1 is held so that it is positioned at the center of the heating element 4.

[0048] The medicinal solution contained in the container 3 is prepared by dissolving a chemical suitable for the various purposes described above in a solvent. To give a detailed example of an insecticidal use, the container 3 is filled with the insecticidal solution, and electricity is applied to the heating element 4, which has a surface temperature of, for example, preferably 70 to 150°C, to heat the surface of the liquid-absorbent wick 1 to, for example, preferably 60 to 135°C. The liquid-absorbent wick for thermal evaporation of this embodiment can stabilize the amount of evaporation of the medicinal solution regardless of whether the heating conditions are continuous or intermittent electrical application, and therefore, the thermal evaporation method of this embodiment can stably exert the effects of the active ingredient regardless of whether the heating conditions are continuous or intermittent electrical application.

[0049] (Product for thermal evaporation) The product for thermal evaporation of this embodiment is composed of the absorbent wick for thermal evaporation of this embodiment and a medicinal solution containing a thermally evaporable active ingredient, a solvent, and water. The absorbent wick for thermal evaporation of this embodiment can stabilize the amount of evaporation of the medicinal solution regardless of whether the heating condition is continuous or intermittent, so the product for thermal evaporation of this embodiment can stably evaporate the medicinal solution regardless of whether the heating condition is continuous or intermittent, and can stably exert the effects of the active ingredient. The product for thermal evaporation of this embodiment can be used indoors or outdoors.

[0050] The product for thermal evaporation of this embodiment can be used to control pests. Specifically, the product for thermal evaporation is composed of the liquid-absorbent wick for thermal evaporation of this embodiment and a chemical solution containing an insecticide as a thermally volatile active ingredient, a solvent, and water, and the active ingredient is evaporated using the product for thermal evaporation, thereby controlling target pests.

[0051] The pests to be controlled are not limited as long as the effects of the present invention can be obtained, and examples include flying pests such as mosquitoes, flies, moths, wasps, stink bugs, dermestid beetles, silverfish, bark beetles, bur moths, and brown moths; cockroaches such as the Smoky brown cockroach, German cockroach, Japanese cockroach, American cockroach, and brown cockroach; spiders, centipedes, ants, house centipedes, millipedes, pill bugs, woodlice, termites, caterpillars, mites, lice, ticks, and bedbugs; and the like.

[0052] When the product for thermal evaporation of this embodiment is used in a method for controlling pests, it is preferable to use it in a closed space such as indoors or inside a room to ensure its effectiveness. Specifically, for example, the product for thermal evaporation of this embodiment is placed on the floor or the like inside a room and electricity is applied, thereby evaporating the insecticide into the room space and controlling pests lurking inside the room. [Example]

[0053] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples.

[0054] [Test Example 1] Evaluation of swelling ratio and absorption rate of absorbent wick The liquid-absorbent wicks shown in Table 2 were prepared and evaluated for swelling ratio and liquid absorption rate. The types of liquid-absorbent wicks in Table 2 are as follows: Synthetic fiber core: An absorbent core bonded and molded using synthetic fibers and thermosetting resin. Kneaded core: An absorbent core made by mixing organic binders, etc., extruding and drying. Baked core: An absorbent core that is mixed with inorganic binders, extruded, and baked.

[0055] (swelling rate) The swelling ratio of each absorbent wick was evaluated according to the following procedure. 1) Each liquid-absorbent wick was immersed in a glass bottle containing a chemical solution having the composition shown in Table 1, and then left to stand in a thermostatic chamber at 100°C. 2) After two days, each specimen was taken out and the core length (total length) and outer diameter were measured. 3) The swelling rate after immersion was calculated from the dimensions before immersion.

[0056] The swelling ratios obtained were evaluated based on the following evaluation criteria, and the results are shown in Table 2. ○: The swelling rate of both the core length (total length) and outer diameter is 105% or less ×: The swelling rate of both the core length (total length) and the outer diameter is greater than 105%

[0057] (Liquid absorption speed) The liquid absorption rate of each absorbent wick was measured according to the following procedure. 1) Each absorbent wick was placed vertically on the bottom of a container filled with a drug solution up to a height of 10 mm. 2) After 10 minutes in the state of 1), the height of the liquid medicine absorbed by the absorbent wick (height from the liquid medicine surface) was measured. 3) The value measured in 2) above was multiplied by 6 to calculate the liquid absorption rate per hour.

[0058] The obtained liquid absorption rates were evaluated based on the following evaluation criteria, and the results are shown in Table 2. ○: Absorption speed is 100 mm / hour or more ×: Absorption rate is less than 100 mm / hour

[0059] [Table 1]

[0060] [Table 2]

[0061] [Test Example 2] The liquid-absorbent wicks shown in Table 3 and the chemical solutions having the compositions shown in Table 1 were evaluated by the following methods, and the results are shown in Table 3. Synthetic fiber cores a to f shown in Table 3 are the synthetic fiber cores of Reference Example 1 shown in Table 2, with the porosity varied. The kneaded core a shown in Table 3 was the liquid-absorbent wick of Reference Example 8 shown in Table 2, and the sintered core a was the liquid-absorbent wick of Reference Example 9 shown in Table 2.

[0062] (Porosity) The porosity of each absorbent wick was measured according to the following procedure. 1) A sample cut to a total length of 30 mm was placed on a balance, and the obtained value was designated as A. 2) A sponge was placed in a petri dish and thoroughly soaked with blue dye solution for measuring porosity (hereinafter referred to as dye solution). 3) The dye solution was allowed to penetrate the sample through the sponge. 4) After confirming that the dye solution had penetrated sufficiently, the sample was placed on a balance and the obtained value was recorded as B. 5) The porosity was calculated using the following formula. WETV / V method = (BA) / ((BA)+(A / ρ)) x 100 (ρ = fiber specific gravity)

[0063] (Liquid absorption speed) The liquid absorption rate of each absorbent wick was measured according to the following procedure. 1) Each absorbent wick was placed vertically on the bottom of a container filled with a chemical solution up to a height of 10 mm. 2) After 10 minutes in the state of 1), the height of the liquid medicine absorbed by the absorbent wick (height from the liquid medicine surface) was measured. 3) The value measured in 2) above was multiplied by 6 to calculate the liquid absorption rate per hour.

[0064] (Liquid absorption rate) The liquid absorption rate of each absorbent wick was measured according to the following procedure. 1) The weight of one absorbent wick when dry was measured. 2) The absorbent wick was immersed in the chemical solution. 3) After the absorbent wick was thoroughly immersed in the chemical solution, the weight of the absorbent wick (weight of the absorbent wick after absorbing the chemical solution) was measured. 4) The liquid absorption rate (%) was calculated using the following formula. Absorption rate (%) = [weight of absorbent wick after absorption (g) - weight of absorbent wick when dry (g)] / weight of absorbent wick when dry (g) × 100

[0065] (Ratio to energizing conditions) The current condition ratio (continuous / intermittent) was calculated by determining the amount of transpiration when current was applied continuously and when current was applied intermittently under each of the conditions shown below, and then calculating the ratio (%) of the amount of transpiration (g) under continuous current application conditions to the amount of transpiration (g) under intermittent current application conditions using the following formula. Formula: Ratio of transpiration (g) under continuous current conditions to transpiration (g) under intermittent current conditions (current condition ratio (continuous / intermittent) (%)) = [transpiration (g) under continuous current conditions / transpiration (g) under intermittent current conditions] × 100 Transpiration under intermittent power conditions The "amount of evaporation (g) under intermittent current application conditions" was determined by the following procedures a1) to a5). a1) 45 mL of the drug solution was filled into a bottle for thermal evaporation, and an inner stopper with an absorbent wick for thermal evaporation attached was inserted to prepare a test sample. a2) The weight of the test specimen was measured using an electronic balance, and this weight was used as the initial specimen weight. a3) The test specimen was attached to a thermal evaporation device [Earth No-Mat (registered trademark), manufactured by Earth Chemical Co., Ltd.], and electricity was turned on to the thermal evaporation device in a room adjusted to 27±2°C. The thermal evaporation device was turned on for 12 hours and off for 12 hours per day, repeatedly. a4) After 14 days (a total of 7 days) from the start of the current application, the power to the heating vaporization device was stopped and the test specimen was collected. The weight of the test specimen was measured using an electronic balance, and this weight was used as the weight of the specimen after 7 days of current application. a5) Calculate the amount of transpiration per day using the formula below and use this as the "amount of transpiration (g) under intermittent power supply conditions." Formula: Daily transpiration rate (g / day) = [(initial specimen weight (g)) - (total specimen weight after 7 days of application (g))] / 7 (days)

[0066] Transpiration rate under continuous power supply conditions The "amount of evaporation (g) under continuous current-carrying conditions" was determined by the following procedures b1) to b5). b1) 45 mL of the drug solution was filled into a bottle for thermal evaporation, and an inner stopper with an absorbent wick for thermal evaporation attached was inserted to prepare a test sample. b2) The weight of the test specimen was measured using an electronic balance, and this was taken as the initial specimen weight. b3) The test specimen was attached to a heating evaporation device [Earth No-Mat (registered trademark), manufactured by Earth Chemical Co., Ltd.], and electricity was turned on to the heating evaporation device in a room adjusted to 27±2°C. b4) Seven days after the start of the electrical current application, the electrical current application to the heating vaporization device was stopped and the test specimen was collected. The weight of the test specimen was measured using an electronic balance and this was the weight of the specimen after 7 days of electrical current application. b5) The amount of transpiration per day was calculated using the following formula and designated as the "amount of transpiration (g) under continuous power supply conditions." Formula: Daily transpiration rate (g / day) = [(initial specimen weight (g)) - (specimen weight after 7 days of application (g))] / 7 (days)

[0067] The obtained current application condition ratio (continuous / intermittent) (%) was evaluated according to the following criteria. A: Over 90%. B: 80% or more but less than 90%. C: 60% or more but less than 80%. D: Less than 60%. E: Absorption is not sufficient and evaporation is insufficient.

[0068] The results are shown in Table 3. In Table 3, "-" indicates that measurement was not possible.

[0069] [Table 3]

[0070] As shown in Table 3, Examples 1 to 5, in which synthetic fibers were bonded and heated with a thermosetting resin and had a liquid absorption rate of 40 to 70%, had a current condition ratio (continuous / intermittent) of 80% or more, and were able to efficiently evaporate the aqueous composition for thermal evaporation regardless of whether the current heating condition was continuous or intermittent. On the other hand, Comparative Example 1 had a low current condition ratio (continuous / intermittent), and in Comparative Examples 2 and 3, the liquid absorption rate was extremely slow, and the liquid absorption could not keep up with the evaporation. [Explanation of symbols]

[0071] 1 Liquid wick 3. Chemical container 4 Heating elements 6 Storage containers

Claims

1. A liquid-absorbent wick for thermal evaporation, for evaporating a medicinal solution containing a thermally evaporable active ingredient, a solvent, and water, The liquid-absorbent wick for thermal evaporation is a liquid-absorbent wick in which synthetic fibers are bonded and heated with a thermosetting resin, The liquid-absorbent wick for thermal evaporation has a liquid absorption rate of 40 to 70%.

2. A method for thermal evaporation using the liquid-absorbent wick for thermal evaporation according to claim 1.

3. A product for thermal evaporation, comprising the liquid-absorbent wick for thermal evaporation according to claim 1 and a medicinal solution containing a thermally evaporable active ingredient, a solvent, and water.

Images